Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Article Swipe
Related Concepts
Vlado Perkovic
,
Meg Jardine
,
Bruce Neal
,
Séverine Bompoint
,
Hiddo J.L. Heerspink
,
David M. Charytan
,
Robert Edwards
,
Rajiv Agarwal
,
George L. Bakris
,
Scott Bull
,
Christopher P. Cannon
,
George Capuano
,
Pei-Ling Chu
,
Dick de Zeeuw
,
Tom Greene
,
Adeera Levin
,
Carol A. Pollock
,
David C. Wheeler
,
Yshai Yavin
,
Hong Zhang
,
Bernard Zinman
,
Gary Meininger
,
Barry M. Brenner
,
Kenneth W. Mahaffey
·
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1811744
· OA: W2939222610
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1811744
· OA: W2939222610
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).
Related Topics
Finding more related topics…